Skip to main content

Gradientech Awarded $634K for Commercialization of AST Platform

NEW YORK – Gradientech said on Friday it has been awarded SEK6.3 million ($634,000) from the Bio-X Accelerate program to help commercialize its QuickMIC diagnostic system.

"The funding received from the Bio-X Accelerate program will definitely help us towards a faster market introduction of the QuickMIC system, both by advancing the production transfer process of our antibiotic panels, and by securing our clinical performance evaluation," Gradientech Product Manager Teresa Fernandez Zafra said in a statement.

The Swedish company earlier said it plans to launch clinical performance studies in support of gaining CE-IVD marking for QuickMIC, a microfluidic-based antibiotic susceptibility testing system.

Bio-X Accelerate is an initiative from Uppsala Bio to support life science companies in eastern and central Sweden.